The potential relationship between QTc interval prolongation and ziprasidone treatment: three cases

Eker S. S., Sarandol A., Akkaya C., Sivrioglu E. Y., Kirli S.

JOURNAL OF PSYCHOPHARMACOLOGY, cilt.23, sa.8, ss.993-996, 2009 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 23 Sayı: 8
  • Basım Tarihi: 2009
  • Doi Numarası: 10.1177/0269881108093843
  • Dergi Adı: JOURNAL OF PSYCHOPHARMACOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.993-996
  • Anahtar Kelimeler: antipsychotic, QTc prolongation, ziprasidone, TORSADE-DE-POINTES, SCHIZOAFFECTIVE DISORDER, ANTIPSYCHOTIC-DRUGS, ACUTE EXACERBATION, DOUBLE-BLIND, 160 MG/DAY, SCHIZOPHRENIA, SAFETY, HALOPERIDOL, MANAGEMENT
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

QTc interval prolongation may appear as a consequence of both typical and atypical antipsychotic treatments. Ziprasidone, which is effective in treating schizophrenia, is associated with QTc prolongation. Although the prolongation of QTc with ziprasidone treatment is often pronounced, there is a scarce number of cases reported about the relationship between ziprasidone and QTc prolongation. Of the three cases presented in this case series, two cases showed values exceeding 0.50 s with ziprasidone treatment.